Clinical trial

Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China

NCT04526028

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Fulvestrant Injectable Product Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Palbociclib Normalized identity: palbociclibView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China

Design: OBSERVATIONAL · Status: UNKNOWN · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeOBSERVATIONAL

Start date2019-09-13

PhaseN/A

Conditions

Breast Cancerverified · MONDO: breast cancer

Fulvestrantunresolved

Palbociclibunresolved

Interventions

Fulvestrant Injectable ProductDRUG

PalbociclibDRUG · verified · RxNorm: palbociclib

Sponsors & collaborators

Tianjin Medical University Cancer Institute and Hospitallead sponsor

Mapped research locations

TianjinTianjin Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04526028 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.